EUVIMEDEUVIMED entdecken
Crossref

Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours

A. Frost, K. Mross, S. Steinbild, S. Hedbom, C. Unger, R. Kaiser, D. Trommeshauser, G. Munzert

Current Oncology · 2012

DOI: 10.3747//co.19.866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2012. Verfasst von A. Frost und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Frost, A., Mross, K., Steinbild, S., Hedbom, S., Unger, C., Kaiser, R., Trommeshauser, D., & Munzert, G. (2012). Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Current Oncology. https://doi.org/10.3747//co.19.866

Vancouver

Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Current Oncology. 2012. doi:10.3747//co.19.866

BibTeX
@article{Frost2012,
  author = {Frost, A. and Mross, K. and Steinbild, S. and Hedbom, S. and Unger, C. and Kaiser, R. and Trommeshauser, D. and Munzert, G.},
  title = {Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours},
  journal = {Current Oncology},
  year = {2012},
  doi = {10.3747//co.19.866}
}
Kostenlos starten →